lncRNAs ABHD11-AS1靶向miR-133a上调EGFR表达促进卵巢癌细胞增殖*

doi:10.3969/j.issn.1671-2587.2022.05.005

临床输血与检验 ›› 2022, Vol. 24 ›› Issue (5): 574-581.DOI: 10.3969/j.issn.1671-2587.2022.05.005

lncRNAs ABHD11-AS1靶向miR-133a上调EGFR表达促进卵巢癌细胞增殖^*

王之丰, 孙昊, 胡电, 金志军, 刘晓军

200003 海军军医大学第二附属医院妇产科

收稿日期:2021-11-26 出版日期:2022-10-20 发布日期:2022-10-31
通讯作者: 刘晓军,女,教授,主要从事妇科恶性肿瘤研究,（E-mail）liuxiaojun20211108@163.com。
作者简介:王之丰（1977-）,男,安徽芜湖人,主治医师,学士,主要从事妇科恶性肿瘤研究,（E-mail）wangzf415@163.com。
基金资助:
^*本课题受上海市老龄化和妇儿健康研究专项计划任务书（No.2020YJZX0210）和计生专项科研课题（应用新技术筛查女性宫颈,妇科恶性肿瘤的研究）（No.19JSZ07）资助

LncRNAs ABHD11-AS1 Targets miR-133a to Upregulate EGFR Expression and Promote Ovarian Cancer cell Proliferation

WANG Zhi-feng, SUN Hao, HU Dian, et al

Department of Gynecology and Obstetrics, Second Affiliated Hospital of Naval Medical University, Shanghai 200003

Received:2021-11-26 Online:2022-10-20 Published:2022-10-31

摘要/Abstract

摘要： 目的研究lncRNAs ABHD11-AS1在卵巢癌细胞和输卵管上皮细胞中的表达,探究其对卵巢癌细胞增殖的影响和作用机制。方法 Real-time PCR检测细胞中lncRNAs ABHD11-AS1和miR-133a的表达,双荧光素酶实验明确二者之间的调控作用;用NC siRNA、ABHD11-AS1 siRNA以及NC mimic、miR-133a mimic和NC inhibitor、miR-133a inhibitor分别转染细胞,CCK-8检测细胞增殖;Real-time PCR以及Western Blot实验检测细胞中EGFR的表达。结果结果表明,lncRNAs ABHD11-AS1在TOV-112D和CaVO3卵巢癌细胞系中的表达水平明显高于TEC细胞,且下调lncRNAs ABHD11-AS1可明显抑制卵巢癌细胞的增殖;ABHD11-AS1与miR-133a的表达呈负相关。双荧光素酶结果显示,转染miR-133a mimic和野生型ABHD11-AS1片段的细胞中荧光素酶的活性显著降低;与输卵管上皮细胞相比,miR-133a在卵巢癌细胞系的表达水平更低。转染miR-133a mimic会显著上调上述两种细胞中miR-133a的表达同时还抑制其增殖和EGFR表达。此外,下调miR-133a可明显促进卵巢癌细胞的增殖以及增加EGFR表达。与此相反,下调lncRNAs ABHD11-AS1明显降低EGFR表达。结论 lncRNAs ABHD11-AS1通过调控miR-133a,上调其下游靶基因EGFR的表达从而促进卵巢癌的发生发展。

关键词: lncRNAs ABHD11-AS1, miR-133a, 卵巢癌, 增殖

Abstract: Objective To investigate the expression of LncRNAs ABHD11-AS1 in ovarian cancer cell and oviductal epithelial cell and explore the effect of LncRNAs ABHD11-AS1 on ovarian cancer cell proliferation. Methods The level of LncRNAs ABHD11-AS1 and miR-133a was detected by Real-time PCR, and interaction between them was confirmed by Dual- Luciferase reporter assay (DR). Cells were transfected with NC siRNA, ABHD11-AS1 as well as siRNA NC mimic, miR-133a mimic and NC inhibitor and miR-133a inhibitor, respectively, and the proliferation was detected by Cell Counting Kit-8 (CCK-8) assay. Real-time PCR and western blotting were performed to detect the EGFR expression. Results Downregulation of lncRNAs ABHD11-AS1 could significantly inhibit the proliferation of ovarian cancer cells. Moreover, lncRNAs ABHD11-AS1 was negatively correlated with the expression of miR-133a. DR results showed that luciferase activity was significantly reduced in cells transfected with miR-133a mimic and wild-type ABHD11-AS1 fragments; and the level of miR-133a was lower in ovarian cancer cell compared to oviductal epithelial cells. Transfection of miR-133a mimic significantly upregulated miR-133a expression in both of these cells and inhibited their proliferation and EGFR expression. In addition, downregulating miR-133a significantly promoted the proliferation of ovarian cancer cells and increased the EGFR expression, while downregulating LncRNAs ABHD11-AS1 significantly decreased the EGFR expression. Conclusion LncRNAs ABHD11-AS1 promoted the malignant behaviors of ovarian cancer by targeting miR-133a to upregulate its downstream target gene EGFR.

Key words: LncRNAsABHD11-AS1, MiR-133a, Ovarian cancer, Proliferation

中图分类号:

R737.31

王之丰, 孙昊, 胡电, 金志军, 刘晓军. lncRNAs ABHD11-AS1靶向miR-133a上调EGFR表达促进卵巢癌细胞增殖^*[J]. 临床输血与检验, 2022, 24(5): 574-581.

WANG Zhi-feng, SUN Hao, HU Dian, et al. LncRNAs ABHD11-AS1 Targets miR-133a to Upregulate EGFR Expression and Promote Ovarian Cancer cell Proliferation[J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2022, 24(5): 574-581.

参考文献

[1] SLATNIK C L P,DUFF E. Ovarian cancer[J]. Nurse Pract,2015,40(9):47-54.
[2] KUJAWA K A,LISOWSKA K M.Ovarian cancer—from biology to clinic[J]. Postepy Hig Med Dosw (Online),2015,69:1275-1290.
[3] HENDERSON J T,WEBBER E M,SAWAYA G F.Screening for ovarian cancer:updated evidence report and systematic review for the US preventive services task force[J]. JAMA,2018,319(6):595-606.
[4] MENON U,KARPINSKYJ C,GENTRY-MAHARAJ A.Ovarian cancer prevention and screening[J]. Obstet Gynecol,2018,131(5):909-927.
[5] CHIEN J,POOLE E M.Ovarian cancer prevention,screening,and early detection:report from the 11th biennial ovarian cancer research symposium[J]. Int J Gynecol Cancer,2017,27(9S Suppl 5):S20-S22.
[6] ZHOU Y,JIN Z J,WANG C C.Glycogen phosphorylase B promotes ovarian cancer progression via Wnt/β-catenin signaling and is regulated by miR-133a-3p[J]. Biomed Pharmacother,2019,120:109449.
[7] ZHANG G L,PIAN C,CHEN Z,et al.Identification of cancer-related miRNA-lncRNA biomarkers using a basic miRNA-lncRNA network[J]. PLoS One,2018,13(5):e0196681.
[8] ZHONG G S,LOU W Y,YAO M Y,et al.Identification of novel mRNA-miRNA-lncRNA competing endogenous RNA network associated with prognosis of breast cancer[J]. Epigenomics,2019,11(13):1501-1518.
[9] ZENG X Y,JIANG X Y,YONG J H,et al.lncRNA ABHD11-AS1,regulated by the EGFR pathway,contributes to the ovarian cancer tumorigenesis by epigenetically suppressing TIMP2[J]. Cancer Med,2019,8(16):7074-7085.
[10] LEI X Y,LI L C,DUAN X Y. Long non-coding RNA ABHD11-AS1 promotes colorectal cancer development through regulation of miR-133a/SOX4 axis[J]. Biosci Rep,2018,38(6):BSR20181386.
[11] ACUNZO M,ROMANO G,WERNICKE D,et al.microRNA and cancer—a brief overview[J]. Adv Biol Regul,2015,57:1-9.
[12] NAM E J,YOON H,KIM S W,et al.microRNA expression profiles in serous ovarian carcinoma[J]. Clin Cancer Res,2008,14(9):2690-2695.
[13] LUO J,ZHOU J H,CHENG Q,et al.Role of microRNA-133a in epithelial ovarian cancer pathogenesis and progression[J]. Oncol Lett,2014,7(4):1043-1048.
[14] PENG W X,KOIRALA P,MO Y Y.LncRNA-mediated regulation of cell signaling in cancer[J]. Oncogene,2017,36(41):5661-5667.
[15] XIN H R,YAN Z F,CAO J.Long non-coding RNA ABHD11-AS1 boosts gastric cancer development by regulating miR-361-3p/PDPK1 signalling[J]. J Biochem,2020,168(5):465-476.
[16] LIU Y,WANG L L,CHEN S,et al.LncRNA ABHD11-AS1 promotes the development of endometrial carcinoma by targeting cyclin D1[J]. J Cell Mol Med,2018,22(8):3955-3964.
[17] ZHANG W,HUANG X,SHI J G.EZH2-mediated lncRNA ABHD11-AS1 promoter regulates the progression of ovarian cancer by targeting miR-133a-3p[J]. Anticancer Drugs,2021,32(3):269-277.
[18] LIU B W,WANG W,SUN S F,et al.Knockdown of lncRNA ABHD11-AS1 suppresses the tumorigenesis of pancreatic cancer via sponging miR-1231[J]. Onco Targets Ther,2020,13:11347-11358.
[19] LAGOS-QUINTANA M,RAUHUT R,YALCIN A,et al.Identification of tissue-specific microRNAs from mouse[J]. Curr Biol,2002,12(9):735-739.
[20] FENG Y,NIU L L,WEI W,et al.A feedback circuit between miR-133 and the ERK1/2 pathway involving an exquisite mechanism for regulating myoblast proliferation and differentiation[J]. Cell Death Dis,2013,4(11):e934.
[21] TANG Y B,PAN J C,HUANG S,et al.Downregulation of miR-133a-3p promotes prostate cancer bone metastasis via activating PI3K/AKT signaling[J]. J Exp Clin Cancer Res,2018,37(1):160.
[22] KINOSHITA T,NOHATA N,FUSE M,et al.Tumor suppressive microRNA-133a regulates novel targets:moesin contributes to cancer cell proliferation and invasion in head and neck squamous cell carcinoma[J]. Biochem Biophys Res Commun,2012,418(2):378-383.
[23] SHI W Y,TANG T T,LI X P,et al.Methylation-mediated silencing of miR-133a-3p promotes breast cancer cell migration and stemness via miR-133a-3p/MAML1/DNMT3A positive feedback loop[J]. J Exp Clin Cancer Res,2019,38(1):429.
[24] GAO L,LI S H,TIAN Y X,et al.Role of downregulated miR-133a-3p expression in bladder cancer:a bioinformatics study[J]. Onco Targets Ther,2017,10:3667-3683.
[25] GAO S H,LIU J,ZHANG H J,et al.Low miR-133a expression is a predictor of outcome in patients with esophageal squamous cell cancer[J]. Eur Rev Med Pharmacol Sci,2016,20(18):3788-3792.
[26] LI W F,CHEN A Q,XIONG L L,et al.miR-133a acts as a tumor suppressor in colorectal cancer by targeting eIF4A1[J]. Tumour Biol,2017,39(5):1010428317698389.
[27] SONG X S,SHI B,HUANG K X,et al.miR-133a inhibits cervical cancer growth by targeting EGFR[J]. Oncol Rep,2015,34(3):1573-1580.
[28] WANG L K,HSIAO T H,HONG T M,et al.microRNA-133a suppresses multiple oncogenic membrane receptors and cell invasion in non-small cell lung carcinoma[J]. PLoS One,2014,9(5):e96765.
[29] ZHENG L,KANG Y,ZHANG L,et al.miR-133a-5p inhibits androgen receptor (AR)-induced proliferation in prostate cancer cells via targeting FUsed in Sarcoma (FUS) and AR[J]. Cancer Biol Ther,2020,21(1):34-42.
[30] CUI W J,ZHANG S,SHAN C L,et al.microRNA-133a regulates the cell cycle and proliferation of breast cancer cells by targeting epidermal growth factor receptor through the EGFR/Akt signaling pathway[J]. FEBS J,2013,280(16):3962-3974.
[31] ROSKOSKI R Jr.Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers[J]. Pharmacol Res,2019,139:395-411.
[32] TAKEDA M,NAKAGAWA K.First- and second-generation EGFR-TKIs are all replaced to osimertinib in chemo-naive EGFR mutation-positive non-small cell lung cancer?[J]. Int J Mol Sci,2019,20(1):146.

lncRNAs ABHD11-AS1靶向miR-133a上调EGFR表达促进卵巢癌细胞增殖^*

LncRNAs ABHD11-AS1 Targets miR-133a to Upregulate EGFR Expression and Promote Ovarian Cancer cell Proliferation

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 9

编辑推荐

Metrics

本文评价

关于本刊

作者中心

在线期刊

访问统计

联系我们

[1]	苏红娥, 钟庆吉, 符春丽, 薛万兴, 林元. 上皮性卵巢癌患者血清miR-222-3p、HE4及CA125的表达及其临床意义*[J]. 临床输血与检验, 2021, 23(3): 371-375.
[2]	施岚, 许良飞, 聂正超, 常文娇, 马筱玲. 金葡菌杀白细胞素S组分LukS-PV抑制急性髓系白血病细胞增殖的机制研究^*[J]. 临床输血与检验, 2020, 22(6): 603-609.
[3]	李桂芳, 刘会兰, 耿良权, 皖湘, 徐修才, 孙自敏, 张世阳. 经典型BCR-ABL1阴性MPNs患者JAK2、CALR及MPL基因突变检测及临床分析[J]. 临床输血与检验, 2020, 22(5): 537-541.
[4]	赵星云, 卞茂红. MicroRNAs与红系生长发育、增殖、分化及凋亡相关性研究进展[J]. 临床输血与检验, 2020, 22(4): 445-448.
[5]	万玲玲, 李明, 单武林, 孙永梅, 薛冰. ROMA指数在绝经前女性卵巢癌诊断和疗效监测中的应用价值^*[J]. 临床输血与检验, 2019, 21(6): 608-611.
[6]	赵继先, 魏红山. 一氧化氮合酶不同亚型在食管上皮的表达及其与胃食管反流病的相关性[J]. 临床输血与检验, 2019, 21(6): 633-636.
[7]	王云洁, 赵绍杰. MicroRNA-31表达与老年女性卵巢癌患者应用紫杉醇联合顺铂化疗的疗效及预后关系的研究*[J]. 临床输血与检验, 2019, 21(3): 236-238.
[8]	陈琪. 血清HE4联合CA125检测在卵巢癌早期诊断及预后评估中的临床价值[J]. 临床输血与检验, 2016, 18(5): 478-481.
[9]	周斌武, 龚国付, 张伟. 四种肿瘤标记物对卵巢癌早期诊断的临床意义[J]. 临床输血与检验, 2016, 18(3): 248-250.